130 related articles for article (PubMed ID: 8166968)
1. Interleukins and contrasuppression induce immune regression of head and neck cancer.
Hadden JW; Endicott J; Baekey P; Skipper P; Hadden EM
Arch Otolaryngol Head Neck Surg; 1994 Apr; 120(4):395-403. PubMed ID: 8166968
[TBL] [Abstract][Full Text] [Related]
2. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
Barrera JL; Verastegui E; Meneses A; Zinser J; de la Garza J; Hadden JW
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):345-51. PubMed ID: 10722007
[TBL] [Abstract][Full Text] [Related]
3. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.
Verastegui E; Barrera JL; Zinser J; Del Rio R; Meneses A; De La Garza J; Hadden JW
Int J Immunopharmacol; 1997; 19(11-12):619-27. PubMed ID: 9669202
[TBL] [Abstract][Full Text] [Related]
4. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.
Meneses A; Verastegui E; Barrera JL; Zinser J; de la Garza J; Hadden JW
Arch Pathol Lab Med; 1998 May; 122(5):447-54. PubMed ID: 9593347
[TBL] [Abstract][Full Text] [Related]
5. The immunopharmacology of head and neck cancer: an update.
Hadden JW
Int J Immunopharmacol; 1997; 19(11-12):629-44. PubMed ID: 9669203
[TBL] [Abstract][Full Text] [Related]
6. Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine.
Feinmesser R; Hardy B; Sadov R; Shwartz A; Chretien P; Feinmesser M
Arch Otolaryngol Head Neck Surg; 2003 Aug; 129(8):874-81. PubMed ID: 12925348
[TBL] [Abstract][Full Text] [Related]
7. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
[TBL] [Abstract][Full Text] [Related]
8. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Wolf GT; Fee WE; Dolan RW; Moyer JS; Kaplan MJ; Spring PM; Suen J; Kenady DE; Newman JG; Carroll WR; Gillespie MB; Freeman SM; Baltzer L; Kirkley TD; Brandwein HJ; Hadden JW
Head Neck; 2011 Dec; 33(12):1666-74. PubMed ID: 21284052
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Moskovitz JM; Moy J; Seiwert TY; Ferris RL
Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
[TBL] [Abstract][Full Text] [Related]
10. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck.
Hadden J; Verastegui E; Barrera JL; Kurman M; Meneses A; Zinser JW; de la Garza J; Hadden E
Int Immunopharmacol; 2003 Aug; 3(8):1073-81. PubMed ID: 12860164
[TBL] [Abstract][Full Text] [Related]
11. Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials.
Browder JP; Chretien PB
Semin Oncol; 1977 Dec; 4(4):431-9. PubMed ID: 339354
[No Abstract] [Full Text] [Related]
12. Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma.
Almokadem S
Curr Mol Pharmacol; 2016; 9(3):226-230. PubMed ID: 26177644
[TBL] [Abstract][Full Text] [Related]
13. Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Moskovitz JM; Ferris RL
J Dent Res; 2018 Jun; 97(6):622-626. PubMed ID: 29489423
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
Freeman SM; Franco JL; Kenady DE; Baltzer L; Roth Z; Brandwein HJ; Hadden JW
Am J Clin Oncol; 2011 Apr; 34(2):173-8. PubMed ID: 20539208
[TBL] [Abstract][Full Text] [Related]
15. Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck.
Suen JY; Richman SP; Livingston RB; Hersh EM; Craig R; Tonymon K
Am J Surg; 1977 Oct; 134(4):474-8. PubMed ID: 911030
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma.
Richtsmeier WJ; Koch WM; McGuire WP; Poole ME; Chang EH
Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1271-7. PubMed ID: 2122909
[TBL] [Abstract][Full Text] [Related]
17. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Recchia F; Candeloro G; Di Staso M; Necozione S; Bisegna R; Bratta M; Tombolini V; Rea S
J Immunother; 2008 May; 31(4):413-9. PubMed ID: 18391754
[TBL] [Abstract][Full Text] [Related]
18. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
[TBL] [Abstract][Full Text] [Related]
19. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
20. Biology and immunology of cancer stem(-like) cells in head and neck cancer.
Qian X; Ma C; Nie X; Lu J; Lenarz M; Kaufmann AM; Albers AE
Crit Rev Oncol Hematol; 2015 Sep; 95(3):337-45. PubMed ID: 25907739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
